menu
    • menu
    [{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Vigil Neuroscience","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Implant","sponsorNew":"Vigil Neuroscience \/ Atlas Venture","highestDevelopmentStatusID":"5","companyTruncated":"Vigil Neuroscience \/ Atlas Venture"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Vida Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Vida Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Vida Ventures"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Morgan Stanley"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Morgan Stanley"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VGL101","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VG-3927","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vigil Neuroscience \/ Not Applicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VGL101","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vigil Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neuroscience \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Vigil Neuroscience

    Menu

    Vigil Neuroscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGL101

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL...

                            Details : VGL101 is a fully human monoclonal antibody targeting human TREM2, which is responsible for maintaining microglial cell function. TREM2 deficiency is believed to be a driver of certain neurodegenerative diseases.

                            Brand Name : VGL101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 26, 2023

                            Lead Product(s) : VGL101

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VG-3927

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vigil Neuroscience Announces Update on Its Small Molecule Trem2 Agonist Program

                            Details : VG-3927 is designed to act as a molecular glue that potentiates the TREM2 signaling response to natural damage ligands and brain-penetrant small molecule.

                            Brand Name : VG-3927

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2023

                            Lead Product(s) : VG-3927

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGL101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101

                            Details : VGL101 is a fully human monoclonal antibody targeting human TREM2, which is responsible for maintaining microglial cell function. TREM2 deficiency is believed to be a driver of certain neurodegenerative diseases.

                            Brand Name : VGL101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 30, 2023

                            Lead Product(s) : VGL101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $112.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Neurodegenerative Disease Biotech Vigil Neuroscience Sets Terms for $112 Million IPO

                            Details : Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

                            Brand Name : VGL101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 03, 2022

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $112.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Morgan Stanley

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Neurodegenerative Disease Biotech Vigil Neuroscience Files For a $100 Million IPO

                            Details : Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

                            Brand Name : VGL101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 19, 2021

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Morgan Stanley

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Le...

                            Details : VGL101, a fully human monoclonal antibody agonist targeting triggering receptor expressed on myeloid cells 2 treatment of patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

                            Brand Name : VGL101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 15, 2021

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Vida Ventures

                            Deal Size : $90.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Vigil Neuroscience Completes Series B Financing to Advance Pipeline of Microglia-targeted Medicines to Treat N...

                            Details : Series B financing further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration which include both a fully human monoclonal antibody, VGL101, and small molecule agonists of triggering receptor on m...

                            Brand Name : VGL101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 18, 2021

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Vida Ventures

                            Deal Size : $90.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Vigil Neuroscience

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Atlas Venture

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodeg...

                            Details : Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline.

                            Brand Name : VGL101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 08, 2020

                            Lead Product(s) : VGL101

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Atlas Venture

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth